User profiles for MATTHEOS BOBOS

Mattheos Bobos

Surgical Pathologist
Verified email at ihu.gr
Cited by 3723

Histopathologic classification and prognostic factors of melanoma: a 2021 update.

M Bobos - Italian journal of dermatology and venereology, 2021 - europepmc.org
Despite the rapid recent advances in molecular analysis of tumors, which allow large-scale
and high-resolution genomics, the" gold standard" for melanoma diagnosis continues to be …

Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung

M Bobos, P Hytiroglou, I Kostopoulos… - The American Journal …, 2006 - journals.lww.com
We assessed the usefulness of several immunohistochemical stains in distinguishing these
two neoplasms, including cytokeratin 7, cytokeratin 20 (CK20), neuron-specific enolase, …

Challenges in sarcoidosis and sarcoid‐like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case

…, C Kemanetzi, C Papageorgiou, M Bobos… - Dermatologic …, 2021 - Wiley Online Library
Sarcoidosis and sarcoid‐like reactions (SLRs) may develop in association with various
malignancies, as well as in association to certain oncologic drugs, including immune checkpoint …

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative …

…, S Glentis, E Bournakis, M Bobos… - Breast cancer research …, 2012 - Springer
In spite the close association of the triple-negative breast cancer immunophenotype with
hereditary breast cancers and the BRCA1 pathway, there is a lack of population studies that …

[HTML][HTML] Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials

…, E Samantas, A Psyrri, H Kourea, M Bobos… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background Tumor infiltrating lymphocytes (TILs) are considered in the prognosis of breast
cancer (BC) patients. Here, we investigated the prognostic/predictive effect of TILs in patients …

[HTML][HTML] Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study

…, I Kostopoulos, E Samantas, I Xanthakis, M Bobos… - BMC cancer, 2008 - Springer
Background The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of
colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has …

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with …

G Fountzilas, M Bobos, A Kalogera-Fountzila… - Cancer …, 2008 - Taylor & Francis
The combination of gemcitabine and gefitinib was evaluated in advanced pancreatic cancer.
Totally, 53 patients were treated with a 7 week cycle of gemcitabine (1,000 mg/m 2 given …

[HTML][HTML] Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel

G Fountzilas, U Dafni, M Bobos, A Batistatou… - PloS one, 2012 - journals.plos.org
Background The aim of the present study was to investigate the efficacy of adjuvant dose-dense
sequential chemotherapy with epirubicin, paclitaxel, and CMF in subgroups of patients …

Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring

…, C Papageorgiou, I Boukovinas, M Bobos… - Journal of the American …, 2020 - Elsevier
Background In retrospective studies, a second primary melanoma (SPM) develops in 2%-20%
of melanoma patients. Scarce evidence exists on the usefulness of total-body …

[HTML][HTML] Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer

…, I Varthalitis, A Psyrri, E Samantas, M Bobos… - Esmo Open, 2019 - Elsevier
Background The clinical relevance of mismatch repair (MMR) status in patients with
nonmetastatic cancer across tumour types remains unclear. Our goal was to investigate the …